20.28
-1.79%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zhejiang Tianyu Pharmaceutical Co
Its shares trade on Shenzhen under the ticker 300702.SZ. It has been listed since 19 September 2017. In the fiscal year to 31 December 2025, it reported revenue of CN¥3.06bn and net income of CN¥139.7m. At that date it held total assets of CN¥6.59bn and shareholders' equity of CN¥3.64bn.
Zhejiang Tianyu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of chemical active pharmaceutical ingredients (API) and intermediates. The company is headquartered in Taizhou, Zhejiang. The company went IPO on 2017-09-19. The firm operates three segments. The Pharmaceutical Intermediates segment include hypertension drugs raw materials, anti-asthma drugs raw materials and anticoagulant drugs raw materials. The Active Pharmaceutical Ingredients (API) segment is engaged in production of high blood pressure drug intermediates, anti-asthma drug intermediates and antiviral drug intermediates. The firm also operates Other segment. The firm sells its products to both domestic and international markets, including Europe, the United States, Japan, South Korea and so on.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 19 Sept 2017
- Employees
- 5,070
- Website
- tianyupharm.com ↗
Leadership
Pay as last reported
- Mr. Yongjun TuChairman of the Board, General Manager, since 2011CN¥1.5m
- Ms. Xiujuan WangChief Financial OfficerCN¥494,800
- Ms. Yan WangDeputy General Manager, Secretary of the BoardCN¥924,400
- Mr. Chuanliang DengDeputy General Manager, Director, since 2020CN¥931,700
- Mr. Fujun WangDeputy General ManagerCN¥724,000
- Mr. Guorong ZhuDeputy General ManagerCN¥927,300
- Ms. Jie LinDirectorCN¥788,000
- Mr. Hanfeng DingIndependent Director
- Mr. Jiyuan ShiIndependent DirectorCN¥80,000
- Mr. Guoyun ZhangIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Zhejiang Tianyu Pharmaceutical employs 5,070 full-time employees for robust production capabilities.
- The company's API segment produces high blood pressure drug intermediates for global markets.
- Pharmaceutical Intermediates segment supplies hypertension drug raw materials to Europe and the US.
Weaknesses
- The company's business is limited to three segments without diversification into other pharmaceutical areas.
- Zhejiang Tianyu Pharmaceutical relies on international markets including Europe and the US for sales.
- The firm's product range focuses on specific drug categories without broader therapeutic coverage.
Opportunities
- Expanding into the growing Asian pharmaceutical market with South Korea and Japan as key partners.
- Increasing demand for antiviral drug intermediates in the global health sector.
- Growing international market presence in Europe and the United States for API products.
Threats
- Dependence on international markets such as Europe and the US for significant revenue streams.
- Competition from other pharmaceutical companies in the API and intermediates segments.
- Potential regulatory changes affecting the pharmaceutical industry in key export markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.